SARAH ROBERTSON: Open Payments
NPI 1215229620 · PEABODY, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$586 in 24 payments from 8 companies in 2025. Trend: 2023 $630 · 2024 $691 · 2025 $586
Food & beverage: $586
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $205 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $86 |
| Novartis Pharmaceuticals Corporation | 4 | $79 |
| Alnylam Pharmaceuticals Inc. | 3 | $76 |
| Amgen Inc. | 3 | $50 |
| E.R. Squibb & Sons, L.L.C. | 2 | $45 |
| HEARTFLOW, INC. | 1 | $23 |
| Novo Nordisk Inc | 1 | $22 |
Products named: WAINUA, JARDIANCE, LEQVIO, AMVUTTRA, FARXIGA, Repatha, CAMZYOS, FFRct.
Industry payments across MA — which companies pay providers there.
